Tislelizumab plus chemo for stage IIIB/IIIC NSCLC
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy as a first treatment for people with stage IIIB or IIIC non-small cell lung cancer. The goal is to see if this approach can shrink the tumor before any other treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IIIB or IIIC non-small cell lung cancer (NSCLC).
- Your tumor does not have common gene changes (EGFR, ALK, or ROS1).
- You have not had any prior treatment for this lung cancer, like chemotherapy, radiation, or surgery.
- You are physically active enough to get around without much help (ECOG status 0 to 2).
- You have not had another cancer that is still being treated or watched closely.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the immunotherapy drug Tislelizumab to standard chemotherapy can shrink stage III non-small cell lung cancer that cannot be surgically removed at first. The goal is to see if this combination makes the cancer small enough for surgery.
This trial tests a combination of platinum-based chemotherapy, large fractionated radiotherapy, and the immunotherapy drug tislelizumab for people with stage IIIB to IV non-squamous non-small cell lung cancer. It aims to see if this approach can help control the cancer without certain gene mutations.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
This study tests a combination of three treatments—an immunotherapy drug called tislelizumab, chemotherapy, and a procedure called BACE—for advanced lung cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two drugs (tislelizumab and anlotinib) for people with advanced lung cancer whose first immunotherapy treatment stopped working. The goal is to see if this new combination can help when the first treatment stopped being effective.
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
Hear when a new NSCLC Stage IIIB, NSCLC Stage IIIC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.